Slide 1: REVTORPYK (gedatolisib) FDA Approval
“celcuity g@ REVTORPYK’ % gedatolisib trietion FDA Approval July 14, 2026
Slide 2: Forward-Looking Statements
_ Forward-Looking Statements This presentation contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements relating to the potential therapeutic benefits of gedatolisib; the size, design and timing o
Slide 3: Agenda
Agenda Intro and Overview Brian Sullivan Chief Executive Officer and Co-Founder REVTORPYK Data & Label Igor Gorbatchevsky, MD Chief Medical Officer REVTORPYK: Commercial Overview Eldon Mayer Chief Commercial Officer Upcoming Milestones Brian Sullivan
Slide 4: Intro and Overview
Intro and Overview Brian Sullivan Chief Executive Officer and Co-Founder
Slide 5: REVTORPYK Is Now FDA-Approved
REVTORPYK Is Now FDA-Approved REVTORPYK is indicated in combination with fulvestrant, with or without palbociclib, for 4 Tl 5 the treatment of HR+/HER2- locally advanced or metastatic a mg breast cancer without a % ie ed A i ISI ib for injection PIK3CA mutation detected following progression on or a
Slide 6: REVTORPYK is well positioned for near- and long-term success
REVTORPYK is well positioned for near- and long-term success, with a $10B+ U.S. market potential across the 1L and 2L+ HR+/HER2- ABC settings LARGEST TWO POSITIVE UNTAPPED DRUG PHASE 3 DEVELOPMENT BEST-IN-CLASS, FIRST-IN-CLASS PAM INHIBITOR READOUTS IN 2L OPPORTUNITY SETTING IN BREAST CANCER Inhibit
Slide 7: REVTORPYK Label & Supporting Data
REVTORPYK Label & Supporting Data Igor Gorbatchevsky, MD Chief Medical Officer
Slide 8: Overview of REVTORPYK U.S. Prescribing Information
Overview of REVTORPYK U.S. Prescribing Information Be wocetsr-rst01 mxonr Sy REVTORPYK sede) fr niecon ae " SST 180 mgivial S intravenous infusion TS) Feutesonetution & \ ™ Uses en Ny Blecard unused om \ cetcuity__— celcuity INDICATION: =» REVTORPYK is indicated in combination with fulvestrant, with
Slide 9: Co-Primary Endpoint: PFS of REVTORPYK Triplet vs. Fulvestrant
‘ Co-Primary Endpoint: PFS of REVTORPYK Triplet vs. Fulvestrant 7.3 months improvement in mPFS Progression-free Survival (%) No. at Risk: Geda+ Palbo + Fuly >4.5x mPFS with REVTORPYK triplet vs fulvestrant alone TT TT TTT? Tt ttt ttt ttt Tt TTT TT 012 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2
Slide 10: Co-Primary Endpoint: PFS of REVTORPYK Doublet vs. Fulvestrant
_ Co-Primary Endpoint: PFS of REVTORPYK Doublet vs. Fulvestrant 5.4 months improvement in mPFS 1004 >3.5x mPFS with REVTORPYK triplet vs fulvestrant alone Progression-free Survival (%) es Pom oe we el as al o-| ox Months No. at Risk: Geda + 130126 93 89 64 63 45 44 33 33 2222 17 16 118 6 5 5 31114 F
Slide 11: Safety Highlights from REVTORPYK Prescribing Information
Safety Highlights from REVTORPYK Prescribing Information SAFETY SUMMARY " Over 80% of adverse reactions were grade 1 or 2 = No dose reductions or discontinuations of REVTORPYK due to hyperglycemia = Stomatitis was generally manageable, occurred early and reduced in treatment frequency and severity w
Slide 12: REVTORPYK Commercial Overview
: celcuity REVTORPYK™ Commercial Overview Eldon Mayer Chief Commercial Officer
Slide 13: Positioning REVTORPYK for strong market adoption in the 2L+
Positioning REVTORPYK for strong market adoption in the 2L+ HR+/HER2-/PIK3CA Wild-Type & Mutant advanced breast cancer setting ati A ili 0 LARGE SIGNIFICANT UNMET WELL COMPELLING VALUE POPULATION NEED IN HR+/HER2- DIFFERENTIATED PROPOSITION 37,000 patients with ADVANCED BREAST Gedatolisib MOA, Best-
Slide 14: Fragmented market with no "Go To" option for PIK3CA Wild-Type
Fragmented market with no “Go To” option for PIK3CA Wild-Type HR+HER2- ABC patients after progressing on initial endocrine therapy Current Treatments Used in 2L PIK3CA Wild-Type ABC Other : Other Chemo-Based Regimen CDK4/6i + ET Xeloda (capecitabine) . Endocrine Mono HER2 ADC mTORC1 Oral SERD Source
Slide 15: Entering Launch with Market and Organizational Momentum
_ Entering Launch with Market and Organizational Momentum ENGAGED KEY STAKEHOLDERS * >1,500 KOLs & Community Breast Cancer Experts * Over 200 Health System Accounts + Major Oncology Organizations + Patient Advocacy Groups « KOLAdvisory Boards celcuity aati PAM PATHWAY & REVTORPYK AWARENESS/ ADVOCACY
Slide 16: Access for REVTORPYK is Designed to Offer Patients and Providers
Access for REVTORPYK is Designed to Offer Patients and Providers Rapid Access with Seamless Support Solutions Comprehensive & Simple Patient Support 0 of top Payer Pathways 100 %o were engaged pre-approval 1 00% of top 36 Strategic Accounts | ce Digital Enrollment were engaged pre-approval aa. of US
Slide 17: REVTORPYK Launch Priorities
- REVTORPYK Launch Priorities @ Oo Al DRIVE AWARENESS RAPID ADOPTION DELIVER ACCESS Rapid engagement of core Unique MOA, Strong Efficacy, Broad payer coverage and REVTORPYK customers Tolerable AE profile world-class patient services 9,000+ 88 1 Academic and Community HCPs Oncology Sales Specialists
Slide 18: Upcoming Milestones
Upcoming Milestones Brian Sullivan Chief Executive Officer and Co-Founder
Slide 19: Key Milestones Achieved and Upcoming in 2026-2027
Key Milestones Achieved and Upcoming in 2026-2027 VIKTORIA-1 MT data presented at ASCO VIKTORIA-1 WT data published in JCO NCCN Guidelines submission NCCN FDA, GUIDELINES VIKTORIA-1 MT data sNDA submission Present additional VIKTORIA-1 mutant and wild-type data at upcoming medical conferences Update
Slide 20: Unlocking the Potential of Treating Cancers That Involve the PI3K/AKT/mTOR Pathway
Unlocking the Potential of Treating Cancers That Involve the PISK/AKT/mTOR Pathway
Slide 21: Thank You
celcuity Thank You ... to the numerous patients and their families who participated in our clinical development program. ... to the clinical investigators, nurses, site coordinators, and countless support staff. ... to the Celcuity team continuously working to deliver this important medicine to pati